EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect

Julieta Afonso iD, Catarina Barbosa-Matos iD, Ricardo Silvestre iD, Joana Pereira-Vieira iD, Samuel Martins Gonçalves, Camille Mendes-Alves, Pier Parpot, Joana Pinto iD, Ângela Carapito iD, Paula Guedes de Pinho iD, Lúcio Santos, Adhemar Longatto-Filho iD und 1 weitere

Cancers · 05.04.2024 · 16 (7) · 1418

DOI: 10.3390/cancers16071418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 05.04.2024. Verfasst von Julieta Afonso und 12 weiteren Autor:innen. Beteiligte Einrichtung: Life and Health Sciences Research Institute (ICVS), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Science and Technology (FCT), Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), ERDF under the scope of NORTE 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced urothelial bladder cancer (UBC) patients are tagged by a dismal prognosis and high mortality rates, mostly due to their poor response to standard-of-care platinum-based therapy. Mediators of chemoresistance are not fully elucidated. This work aimed to study the metabolic profile of advanced UBC, in the context of cisplatin resistance. Three isogenic pairs of parental cell lines (T24, HT1376 and KU1919) and the matching cisplatin-resistant (R) sublines were used. A set of functional assays was used to perform a metabolic screening on the cells. In comparison to the parental sublines, a tendency was observed towards an exacerbated glycolytic metabolism in the cisplatin-resistant T24 and HT1376 cells; this glycolytic phenotype was particularly evident for the HT1376/HT1376R pair, for which the cisplatin resistance ratio was higher. HT1376R cells showed decreased basal respiration and oxygen consumption associated with ATP production; in accordance, the extracellular acidification rate was also higher in the resistant subline. Glycolytic rate assay confirmed that these cells presented higher basal glycolysis, with an increase in proton efflux. While the results of real-time metabolomics seem to substantiate the manifestation of the Warburg phenotype in HT1376R cells, a shift towards distinct metabolic pathways involving lactate uptake, lipid biosynthesis and glutamate metabolism occurred with time. On the other hand, KU1919R cells seem to engage in a metabolic rewiring, recovering their preference for oxidative phosphorylation. In conclusion, cisplatin-resistant UBC cells seem to display deep metabolic alterations surpassing the Warburg effect, which likely depend on the molecular signature of each cell line.

Schlagwörter

Stichwörter der Autor:innen

Warburg effectcisplatin resistanceglucoseglutamatelactatelipid metabolismurothelial bladder cancer

Autor:innen und Institutionen

  • Life and Health Sciences Research Institute (ICVS), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal.
  • ICVS/3B's-PT Government Associate Laboratory, 4710-057 Braga, Portugal.
  • CQUM, Centre of Chemistry, Chemistry Department, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal.
  • CEB-Centre of Biological Engineering, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal.
  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal.
  • UCIBIO-Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.

ORCID-Profile: Julieta Afonso, Catarina Barbosa-Matos, Ricardo Silvestre, Joana Pereira-Vieira, Joana Pinto, Ângela Carapito, Paula Guedes de Pinho, Adhemar Longatto-Filho, Fátima Baltazar

Förderung

  • Foundation for Science and Technology (FCT)
  • Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)
  • ERDF under the scope of NORTE 2020
  • National funds from the FCT in the scope of the UCIBIO
  • Associate Laboratory i4HB
  • Portuguese Cancer League—North Branch
  • Scientific Employment Stimulus

Zitieren

APA

Afonso, J., Barbosa-Matos, C., Silvestre, R., Pereira-Vieira, J., Gonçalves, S. M., Mendes-Alves, C., Parpot, P., Pinto, J., Carapito, Â., Guedes de Pinho, P., Santos, L., Longatto-Filho, A., & Baltazar, F. (2024). Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect. Cancers, 16(7), 1418. https://doi.org/10.3390/cancers16071418

Vancouver

Afonso J, Barbosa-Matos C, Silvestre R, Pereira-Vieira J, Gonçalves SM, Mendes-Alves C, et al. Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect. Cancers. 2024;16(7):1418. doi:10.3390/cancers16071418

BibTeX
@article{Afonso2024,
  author = {Afonso, Julieta and Barbosa-Matos, Catarina and Silvestre, Ricardo and Pereira-Vieira, Joana and Gonçalves, Samuel Martins and Mendes-Alves, Camille and Parpot, Pier and Pinto, Joana and Carapito, Ângela and Guedes de Pinho, Paula and Santos, Lúcio and Longatto-Filho, Adhemar and Baltazar, Fátima},
  title = {Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {7},
  pages = {1418},
  doi = {10.3390/cancers16071418}
}
Kostenlos starten →